Facebook
Twitter
LinkedIn

Media Center

FAST, Fellows and CARB-X Update January 2020
Facebook
Twitter
LinkedIn

Fast & Fellows Round-Up

CARB-X News

  • CARB-X funds VenatoRx Pharmaceuticals to support the development of a new class of oral antibiotics to treat multi-drug-resistant gonorrhea Read More
  • CARB-X funds Vedanta Biosciences to accelerate the development of a new category of oral therapeutics to help a patient’s microbiota fight drug-resistant bacteria Read More
  • CARB-X backs Centauri to advance a new platform that combines antibiotic power with the ability to boost the immune system to fight infections caused by drug-resistant bacteria Read More
  • CARB-X funds TAXIS Pharmaceuticals to accelerate development of innovative efflux pump inhibitors (EPIs), a new drug class that would impair bacteria’s ability to fight antibiotics Read More
  • CARB-X funds Trellis Bioscience to support the development of a monoclonal antibody designed to disrupt superbugs’ protective coating so that antibiotics can kill them Read More